Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses

AIP is significantly associated with a range of CVD and metabolic disorders. These findings suggest that AIP could serve as a valuable biomarker for diagnosing and assessing risk in CVD and metabolic conditions. However, AIP was not significantly associated with all-cause mortality in CAD, stroke in CAD, or NAFLD, highlighting the need for further research to evaluate its clinical utility in diverse patient populations. Clinicians may consider incorporating AIP into broader risk assessment strategies, particularly for patients with existing CVD or metabolic conditions. Additionally, AIP holds potential as a screening tool for large populations, offering clinicians a simple and cost-effective way to identify individuals at higher risk.